Early experience with critically ill patients with COVID-19 in Montreal
- PDF / 423,444 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 52 Downloads / 167 Views
REPORTS OF ORIGINAL INVESTIGATIONS
Early experience with critically ill patients with COVID-19 in Montreal Expe´riences initiales avec les patients atteints de la COVID-19 en e´tat critique a` Montre´al . Alexandre Noe¨l, MD . Yiorgos Alexandros Cavayas, MD, MSc Veronique Brunette, MD . David Williamson, BPharm, PhD . Anne Julie Frenette, PharmD, PhD . Christine Arsenault, MD . Patrick Bellemare, MD . Colin Lagrenade-Verdant, MD . Soazig LeGuillan, MD . Emilie Levesque, MD . Yoan Lamarche, MD . Marc Giasson, MD . Philippe Rico, MD . Yanick Beaulieu, MD . Pierre Marsolais, MD . Karim Serri, MD . Francis Bernard, MD . Martin Albert, MD Received: 16 June 2020 / Revised: 21 August 2020 / Accepted: 31 August 2020 Ó Canadian Anesthesiologists’ Society 2020
Abstract Purpose Montreal has been the epicentre of the coronavirus disease (COVID-19) pandemic in Canada. Given the regional disparities in incidence and mortality in the general population, we aimed to describe local characteristics, treatments, and outcomes of critically ill COVID-19 patients in Montreal.
Methods A single-centre retrospective cohort of consecutive adult patients admitted to the intensive care unit (ICU) of Hoˆpital du Sacre´-Coeur de Montre´al with confirmed COVID-19 were included. Results Between 20 March and 13 May 2020, 75 patients were admitted, with a median [interquartile range (IQR)] age of 62 [53–72] yr and high rates of obesity (47%), hypertension (67%), and diabetes (37%). Healthcare-
Y. A. Cavayas, MD, MSc (&) K. Serri, MD F. Bernard, MD M. Albert, MD Service de Soins Intensifs, Hoˆpital du Sacre´-Coeur de Montre´al, CIUSSS du Nord-de l’ıˆle de Montre´al, De´partement de Me´decine, Universite´ de Montre´al, 5400 Gouin Ouest, Montreal, QC H4J 1C5, Canada e-mail: [email protected]
De´partement de Pharmacie, Hoˆpital du Sacre´-Coeur de Montre´al, CIUSSS du Nord-de l’ıˆle de Montre´al, Faculte´ de Pharmacie, Universite´ de Montre´al, Montreeal, QC, Canada
ERESI (Equipe de Recherche En Soins Intensifs), Centre de recherche de l’Hoˆpital du Sacre´-Coeur de Montre´al, Montreal, QC, Canada A. Noe¨l, MD V. Brunette, MD P. Bellemare, MD C. Lagrenade-Verdant, MD E. Levesque, MD Y. Lamarche, MD M. Giasson, MD P. Rico, MD Y. Beaulieu, MD P. Marsolais, MD Service de Soins Intensifs, Hoˆpital du Sacre´-Coeur de Montre´al, CIUSSS du Nord-de l’ıˆle de Montre´al, De´partement de Me´decine, Universite´ de Montre´al, 5400 Gouin Ouest, Montreal, QC H4J 1C5, Canada D. Williamson, BPharm, PhD ERESI (Equipe de Recherche En Soins Intensifs), Centre de recherche de l’Hoˆpital du Sacre´-Coeur de Montre´al, Montreal, QC, Canada
A. J. Frenette, PharmD, PhD De´partement de Pharmacie, Hoˆpital du Sacre´-Coeur de Montre´al, CIUSSS du Nord-de l’ıˆle de Montre´al, Faculte´ de Pharmacie, Universite´ de Montre´al, Montreeal, QC, Canada C. Arsenault, MD De´partement de Biologie Me´dicale, Hoˆpital du Sacre´-Coeur de Montre´al, CIUSSS du Nord-de l’ıˆle de Montre´al, De´partement de Microbiologie, Universite´ de Montre´al, M
Data Loading...
